Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Grifols

Founders Josep Antoni Gru00edfols i Roig

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$25M
Portfolio companies 5
Rounds per year 0.07
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 3
Key employees Soon

Areas of investment

  • Biotechnology
  • Medical
  • Therapeutics
  • Health Care
  • Medical Device
Summary

Grifols appeared to be the Corporate Investor, which was created in 1940. The main office of represented Corporate Investor is situated in the Barcelona. The company was established in Europe in Spain.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - Belgium. Among the most successful fund investment fields, there are Biotechnology, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Celyad, GigaGen

The typical case for the fund is to invest in rounds with 1-2 participants. Despite the Grifols, startups are often financed by Prolog Ventures, OrbiMed, Fisk Ventures. The meaningful sponsors for the fund in investment in the same round are Hunza Ventures, Life Sciences Research Partners V.Z.W.. In the next rounds fund is usually obtained by Perceptive Advisors, Hunza Ventures.

The typical startup value when the investment from Grifols is 10-50 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Grifols works on 9 percentage points less the average amount of lead investments. Considering the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2009. The higher amount of exits for fund were in 2015.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Grifols:
Typical Co-investors
Grifols is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Grifols:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aries Holding BV Amsterdam, Noord-Holland, The Netherlands
Bitpie Australia, New South Wales, Sydney
Cellular Bioengineering Hawaii, Honolulu, United States
EDEX -
SAYJ Global Partners -
Sky9 Capital China, Shanghai, Shanghai
Sports.ru Moscow City, Moscow Oblast, Russian Federation
Stripes New York, New York, United States
Tao Group Las Vegas, Nevada, United States
TechBloc -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

GigaGen

Biotechnology
Genetics
Medical
Therapeutics
$35M07 Jul 2017 South San Francisco, California, United States

Singulex

Biotechnology
Health Care
Life Science
Medical
$50M01 Jun 2016 California, United States

Alkahest

Biotechnology
Health Care
Medical
$37M04 Mar 2015 California, United States

Celyad

Biotechnology
Medical Device
Therapeutics
$22M08 May 2013 Walloon Brabant

VCN Biosciences

Biotechnology
09 Jul 2012 Barcelona, Catalonia, Spain

Celyad

Biotechnology
Medical Device
Therapeutics
$8M19 Jan 2009 Walloon Brabant

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Grifols?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: